DEVELOPMENT OF ENGINEERED ANTIBODIES SPECIFIC FOR THE MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR: A PROMISING CANDIDATE FOR TARGETED THERAPY OF OVARIAN CANCER

YUAN, Q.A., SIMMONS, H.H., & ROBINSON, M.K.. (2006). DEVELOPMENT OF ENGINEERED ANTIBODIES SPECIFIC FOR THE MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR: A PROMISING CANDIDATE FOR TARGETED THERAPY OF OVARIAN CANCER. MOLECULAR CANCER THERAPEUTICS, 5(8), 2096-2105. SID. https://sid.ir/paper/655601/en

YUAN Q.A., SIMMONS H.H., ROBINSON M.K.. DEVELOPMENT OF ENGINEERED ANTIBODIES SPECIFIC FOR THE MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR: A PROMISING CANDIDATE FOR TARGETED THERAPY OF OVARIAN CANCER. MOLECULAR CANCER THERAPEUTICS[Internet]. 2006;5(8):2096-2105. Available from: https://sid.ir/paper/655601/en

Q.A. YUAN, H.H. SIMMONS, and M.K. ROBINSON, “DEVELOPMENT OF ENGINEERED ANTIBODIES SPECIFIC FOR THE MULLERIAN INHIBITING SUBSTANCE TYPE II RECEPTOR: A PROMISING CANDIDATE FOR TARGETED THERAPY OF OVARIAN CANCER,” MOLECULAR CANCER THERAPEUTICS, vol. 5, no. 8, pp. 2096–2105, 2006, [Online]. Available: https://sid.ir/paper/655601/en